Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
UCBCares: Providing Dedicated Patient Support
Clinical studies at UCB: How are medicines made and tested?
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
Twitter Feed
-
Every October 20th the world comes together to mark #WorldOsteoporosisDay, a day dedicated to raising global awareness of a silent epidemic that affects 1 in 3 women and 1 in 5 men over the age of 50 worldwide #osteoporosis #UCB https://t.co/ciuyqymgcK
— UCB News (@ucb_news) 20.10.2019 -
UCB continues to be committed to the unique needs of the #dermatology patient community, both in treatment and improving the patient experience. #FallCIinical https://t.co/jWjjZwGeBG
— UCB News (@ucb_news) 19.10.2019 -
#DYK psoriasis on the head and neck can cause a high degree of emotional distress to patients? Women in particular report significant impact on their quality of life from visible #psoriasis lesions. #FallClinical https://t.co/Xk691VWLOy
— UCB News (@ucb_news) 18.10.2019
